Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia

nork Uy, Geoffrey L., Assouline, Sarit, Young, Anne-Marie, Blotner, Steven, Higgins, Brian, Chen, Lin-Chi, Yee, Karen
Argitaratua izan da Invest New Drugs (2020)

Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study

nork Meric-Bernstam, Funda, Hurwitz, Herbert, Kanwal Pratap Singh, Raghav, McWilliams, Robert R., Fakih, Marwan, VanderWalde, Ari, Swanton, Charles, Kurzrock, Razelle, Burris, Howard, Sweeney, Christopher, Bose, Ron, Spigel, David R., Beattie, Mary S., Blotner, Steven, Stone, Alyssa, Schulze, Katja, Cuchelkar, Vaikunth, Hainsworth, John
Argitaratua izan da Lancet Oncol (2019)

Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia

nork Andreeff, Michael, Kelly, Kevin R., Yee, Karen, Assouline, Sarit, Strair, Roger, Popplewell, Leslie, Bowen, David, Martinelli, Giovanni, Drummond, Mark W., Vyas, Paresh, Kirschbaum, Mark, Iyer, Swaminathan Padmanabhan, Ruvolo, Vivian, Nogueras González, Graciela M., Huang, Xuelin, Chen, Gong, Graves, Bradford, Blotner, Steven, Bridge, Peter, Jukofsky, Lori, Middleton, Steve, Reckner, Monica, Rueger, Ruediger, Zhi, Jianguo, Nichols, Gwen, Kojima, Kensuke
Argitaratua izan da Clin Cancer Res (2015)

Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

nork Reis, Bernhard, Jukofsky, Lori, Chen, Gong, Martinelli, Giovanni, Zhong, Hua, So, W. Venus, Dickinson, Michael J., Drummond, Mark, Assouline, Sarit, Hashemyan, Maneja, Theron, Michel, Blotner, Steven, Lee, Je-Hwan, Kasner, Margaret, Yoon, Sung-Soo, Rueger, Ruediger, Seiter, Karen, Middleton, Steven A., Kelly, Kevin R., Vey, Norbert, Yee, Karen, Nichols, Gwen, Chen, Lin-Chi, Pierceall, William E.
Argitaratua izan da Haematologica (2016)